Long-term outcomes of severe rheumatic mitral stenosis after undergoing percutaneous mitral commissurotomy and mitral valve replacement: A 10-year experience

Wasinee Promratpan, Nonthikorn Theerasuwipakorn*, Vorarit Lertsuwunseri, Suphot Srimahachota

Division of Cardiovascular Medicine, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Cardiac Center, King Chulalongkorn Memorial Hospital, 10330, Bangkok, Thailand

Introduction
Rheumatic heart disease (RHD) is one of the most common acquired valvular heart diseases.1 RHD has declined dramatically worldwide, though in low- to middle-income countries, RHD is an important cause of death and disability. The prevalence of RHD ranged from 3 to > 1,000 cases per 100,000 depending on regional endemic.2,3 Mitral stenosis (MS), the most common manifestation of RHD, can cause atrial fibrillation (AF), ischemic stroke, pulmonary hypertension, and heart failure. The treatment strategies for clinically significant rheumatic MS are percutaneous mitral commissurotomy (PTMC) and mitral valve replacement (MVR). PTMC is the treatment of choice in patients with favorable clinical and valvular anatomical characteristics while some patients with contraindication to PTMC should undergo MVR.4,5

Treatment results are variable depending on many factors including patient and mitral valve (MV) characteristics, as well as, the local expertise of interventionalists and surgeons.6-10 Moreover, long-term outcomes of patients with severe rheumatic MS who underwent PTMC or MVR are limited. The aims of this study are to evaluate long-term outcomes, procedural success rate and complications of these patients.

Materials and Methods

Study design
This is a single-center retrospective cohort study conducted in patients with age ≥ 18 years old and diagnosed of a clinically significant severe rheumatic MS, mitral valve area (MVA) < 1.5 cm², who underwent either PTMC or MVR including MVR with tricuspid valve repair (TVR) during 2010 to 2020. Patients who had inadequate follow-up time (< 6 months), indication for other cardiac surgery or previously underwent mitral valve intervention were excluded. The patient's information was reviewed from OPD records, IPD records and civil registration. This study was approved by the Institutional Review Board (IRB no.672/63).

Keywords:
Long-Term Outcome
Mitral Valve Replacement
Percutaneous Mitral Commissurotomy
Rheumatic Mitral Stenosis

Abstract

Introduction: Percutaneous mitral commissurotomy (PTMC) and mitral valve replacement (MVR) are treatments of choice for severe rheumatic mitral stenosis (MS). Data regarding the long-term outcomes of patients who underwent PTMC and MVR are limited.

Methods: A retrospective cohort study was conducted to evaluate the long-term outcomes of patients with severe rheumatic MS who underwent PTMC or MVR between 2010 to 2020. The primary outcome comprised of all-cause death, stroke or systemic embolism, heart failure hospitalization and re-intervention. Cox regression was used to investigate predictors of the primary outcome.

Results: 264 patients were included in analysis, 164 patients (62.1%) in PTMC group and 100 patients in MVR group (37.9%). The majority were females (80.7%) and had atrial fibrillation (68.6%). The mean age was 49.52 (SD: 13.03) years old. MVR group had more age and AF, higher Wilkins’ score with smaller MVA. Primary outcome occurred significantly higher in PTMC group (37.2% vs 22%, P = 0.002), as well as, re-intervention (18.3% vs 0%, P < 0.001). However, all-cause mortality, stroke or systemic embolism and heart failure hospitalization were not significantly different. In multivariate Cox regression analysis, PTMC (HR 1.94; 95%CI 1.14, 3.32; P = 0.015), older age (HR 1.03; 95%CI 1.01, 1.06; P = 0.009) and SPAP > 50 mmHg (HR 2.99; 95%CI 1.01, 8.84; P = 0.047) were the only predictors of primary outcome.

Conclusion: Primary outcome occurred in PTMC group more than MVR group which was driven by re-intervention. However, all-cause mortality, stroke or systemic embolism and heart failure hospitalization were not significantly different.
Procedures
The treatment strategy, including the prosthetic valve types (bioprosthesis or mechanical valve) and the need for concomitant tricuspid valve annuloplasty (TVA) in case of MVR, was decided by the heart team which consisted of cardiothoracic surgeons, cardiologists, echocardiographic specialists and anesthesiologists.

PTMC was performed with the Inoue commissurotomy technique using Inoue single balloon (Toray Industries, Inc., NY, United State) and transesophageal guided atrial septostomy and commissurotomy.11 A balloon diameter and catheter size were chosen according to the patient height. Echocardiography, as well as left and right cardiac catheterization, were performed at baseline and after PTMC. Important parameters namely MVA, mean pressure gradient (PG) across MV, Wilkins’ score, mitral regurgitation (MR) grading and pulmonary artery pressure were recorded.

Outcomes
The primary outcome was composite of all-cause death, stroke or systemic embolism, heart failure hospitalization and re-intervention rate. Secondary outcomes were all-cause death, stroke or systemic embolism, heart failure hospitalization, re-intervention rate, PTMC success rate, periprocedural complications, valvular infection and serious bleeding (The Bleeding Academic Research Consortium (BARC) definition type 3 or more).12 PTMC success rate was defined as MVA after procedure > 1.5 cm² or more than twice of the preprocedural value and no worsening of MR more than grade 2+).13

Statistical analysis
Categorical variables were presented as frequency and percentage and analyzed using a Chi-square test or Fisher’s exact test as appropriate. Continuous variables are presented as the mean with standard deviation (SD) or median with interquartile range (IQR) and analyzed using a t-test or Mann-Whitney test as appropriate. The periprocedural complications were not analyzed due to the different complications found between both groups. Univariate and multivariate Cox regression, adjusted for covariates with a p-value from the univariable model was less than 0.15, were performed to find the hazard ratio (HR). The Kaplan-Meier curve with log-rank tests was used for survival analysis. All analyses required a value of p<0.05 for statistical significance. All statistical analyses were performed using SPSS Statistics version 22.0 (IBM Corp., Armonk, NY, USA) and STATA/SE version 14.1 (StataCorp., Texas, USA).

Results
Baseline characteristics
Two hundred and sixty-four patients were included in the analysis, 164 patients (62.1%) in the PTMC group and 100 patients in the MVR group (37.9%) (Figure 1). The

![Figure 1. Outcomes of patients with severe rheumatic MS who underwent PTMC and MVR. Bold value denotes statistical significance (P < 0.05). MS = Mitral stenosis, MVR = Mitral valve replacement, PTMC = Percutaneous mitral commissurotomy.](image-url)

102 | J Cardiovasc Thorac Res, 2022, 14(2), 101-107
The majority were females (80.7%) and had AF (68.6%). The mean age was 49.52 (SD: 13.03) years old. Hypertension (HT), type 2 diabetes mellitus (DM), dyslipidemia and chronic kidney disease (CKD) were found 14.4%, 10.2%, 6.8% and 1.9%, respectively. The most common indications for MV intervention were dyspnea (50.8%), heart failure (37.1%) and new-onset AF (14.4%) (Table 1).

In the PTMC group, the mean age was 47.38 (SD: 13.38) years old and 53% had AF, significant lower when compared to the MVR group whose mean age was 53.04 (SD: 11.69) years old (P = 0.001) and 94% had AF (P < 0.001). The comorbidities and indications for MV intervention in both groups were comparable. The only different indication was intervention before pregnancy or undergoing major surgery which only led to PTMC (5.5%) but not surgery (P = 0.018). In term of echocardiographic parameters, MVR group had more severe MV morphology: mean Wilkins’ score was 9.47 (SD: 2.01) vs 8.1 (SD: 1.56), P < 0.001; mean MVA using planimetry was 0.85 (SD: 0.32) vs 0.94 (SD: 0.27), P = 0.016; mean MVA using pressure half time (PHT) was 0.89 (SD: 0.27) vs 0.98 (SD: 0.26), P = 0.005. However, mean PG across MV and estimated right ventricular systolic pressure (RVSP) was not significantly different. The median follow up time was 62.5 (IQR: 27.25, 101.0) months in the PTMC group and 57.0 (IQR: 28.25, 102.75) months in the MVR group which were comparable in both groups (Table 1).

### Treatment outcomes

**PTMC group**

The primary outcome occurred in 61 patients (37.2%), consisted of all-cause mortality 17.1%, stroke or systolic embolism 4.3%, heart failure hospitalization 11.6% and re-intervention 18.3% (Figure 1). The success rate of PTMC was 67.1%, however, periprocedural complications occurred in 14 patients (8.5%) including cardiac tamponade in 5 patients (3%), severe MR in 8 patients (4.9%) and 1 death (0.6%). The valvular infection and serious bleeding (BARC ≥ 3) were 1.2% and 8.5%, respectively. The median length of hospital stays was 1 (IQR: 1, 2) days (Table 2). During the follow-up, 30 patients (18.3%) were undergoing re-intervention with a median intervention-free period of 40.0 (IQR: 10.0, 77.5) months. The indications for re-intervention were severe

---

**Table 1. Baseline characteristics**

|               | All patients (N = 264) | PTMC group (N=164) | MVR group (N=100) | P value |
|---------------|------------------------|--------------------|-------------------|---------|
| Mean age, years | 49.52 ± 13.03 | 47.38 ± 13.38 | 53.04 ± 11.69 | 0.001   |
| Female, (%)    | 213 (80.7%)          | 131 (79.9%)       | 82 (82%)         | 0.672   |
| Atrial fibrillation, (%) | 181 (68.6%) | 87 (53%)       | 94 (94%)         | < 0.001 |
| Comorbidity, (%) |                      |                    |                  |         |
| Type 2 diabetes mellitus | 27 (10.2%) | 18 (11%)         | 9 (9%)           | 0.626   |
| Hypertension    | 38 (14.4%)           | 24 (14.6%)        | 14 (14%)         | 0.912   |
| Dyslipidemia    | 18 (6.8%)            | 9 (5.5%)          | 9 (9%)           | 0.262   |
| Chronic kidney disease, (GFR<60 ml/min/1.73 m²) | 5 (1.9%) | 4 (2.4%)         | 1 (1%)           | 0.653   |
| Indication, (%) |                      |                    |                  |         |
| Dyspnea        | 134 (50.8%)          | 84 (51.2%)        | 50 (50%)         | 0.897   |
| Heart failure  | 98 (37.1%)           | 56 (34.1%)        | 42 (42%)         | 0.181   |
| Stroke and systemic embolism | 30 (11.4%) | 18 (11%)        | 12 (12%)         | 0.782   |
| New onset atrial fibrillation | 38 (14.3%) | 29 (17.7%)       | 9 (9%)           | 0.054   |
| SPAP > 50 mmHg  | 8 (3%)               | 6 (3.7%)          | 2 (2%)           | 0.714   |
| Planned pregnancy or major surgery | 9 (3.4%) | 9 (5.5%)         | 0 (0%)           | 0.018   |

**Preprocedural Echocardiographic data**

|               | All patients (N = 264) | PTMC group (N=164) | MVR group (N=100) | P value |
|---------------|------------------------|--------------------|-------------------|---------|
| Wilkins’ score | 8.59 ± 1.85            | 8.10 ± 1.56        | 9.47 ± 2.01       | < 0.001 |
| Wilkins’ score ≥ 8, (%) | 192 (72.7%) | 112 (68.3%)       | 80 (80%)         | < 0.001 |
| MVA by planimetry, cm² | 0.91 ± 0.30 | 0.94 ± 0.27       | 0.85 ± 0.32       | 0.016   |
| MVA by PHT, cm² | 0.96 ± 0.28            | 0.98 ± 0.26        | 0.89 ± 0.27       | 0.005   |
| Mean PG, mmHg | 12.67 ± 5.81           | 12.74 ± 6.11       | 12.56 ± 5.5       | 0.823   |
| RVSP, mmHg    | 54.77 ± 22.77          | 54.19 ± 23.10      | 55.70 ± 21.23     | 0.631   |
| Mean PAP, mmHg | 32.83 ± 12.00         | 34.48 ± 13.50      | 31.58 ± 11.27     | 0.269   |
| Follow up time*, month | 62.0 (28.0, 102.0) | 62.5 (27.25, 101.0) | 57.0 (28.25, 102.75) | 0.966   |

* Median with interquartile range

GFR = Glomerular filtration rate, MVA = Mitral valve area, MVR = Mitral valve replacement, PAP = Pulmonary arterial pressure, PHT = Pressure-half time, PG = pressure gradient, PTMC = Percutaneous mitral commissurotomy, RVSP = Right ventricular systolic pressure, SPAP = Systolic pulmonary arterial pressure.
MS 70% and severe MR 30%. Re-intervention was done with PTMC in 7 patients (23.3%) and MVR in 23 patients (76.7%) as shown in the Supplementary Table (Online resource 1).

After PTMC, MVA by planimetry (0.94, SD: 0.27 vs 1.49 SD: 0.39, \( P < 0.001 \)) and MVA by PHT (0.98, SD: 0.26 vs 1.56 SD: 0.38, \( P < 0.001 \)) were significantly improved. Mean PG across MV measured with echocardiography (12.74 SD: 6.11 vs 6.12 SD: 2.9, \( P < 0.001 \)) and cardiac catheterization (12.63 SD: 6.71 vs 5.87 SD: 3.79, \( P < 0.001 \)) was decrease by a half. RVSP, systolic pulmonary artery pressure (PAP) and mean PAP were also decrease significantly (\( P < 0.001 \) for all parameters) (Table 3).

**MVR group**

Patients with contraindication to PTMC were undergoing MVR. Contraindications were the presence of left atrial thrombus (22%), at least moderate MR (43%), severe tricuspid regurgitation requiring surgery (26%), unfavorable MV characteristics (13%), severe bi-commisural fusion (1%).

Of all patients in the MVR group, MVR alone was done in 72% while 28% underwent MVR and concomitant TVA. Seventy-four patients (74%) were implanted with a

| Table 2. Outcomes of PTMC and MVR groups |
|------------------------------------------|
| **PTMC group** (N, 164) | **MVR group** (N, 100) | **P value** |
|--------------------------|------------------------|-------------|
| **Primary outcome:** all-cause death; stroke or systemic embolism; heart failure hospitalization and re-intervention; (%) | 61 (37.2%) | 22 (22%) | 0.002 |
| **All-causes mortality:** (%) | 28 (17.1%) | 15 (15%) | 0.658 |
| **Stroke or systemic embolism:** (%) | 7 (4.3%) | 5 (5%) | 0.963 |
| **Heart failure hospitalization:** (%) | 19 (11.6%) | 7 (7%) | 0.101 |
| **Re-intervention:** (%) | 30 (18.3%) | 0 (0%) | <0.001 |
| **Periprocedural complication:** (%) | 14 (8.5%) | 16 (16%) | N/A |
| Cardiac tamponade | 5 (3%) | 0 | |
| Severe MR | 8 (4.9%) | 0 | |
| Re-sternotomy | N/A | 4 (4%) | |
| AKI required dialysis | 0 | 4 (4%) | |
| Complete heart block | | | |
| - Temporary pacemaker | 0 | 3 (3%) | |
| - Permanent pacemaker | 0 | 1 (1%) | |
| Death | 1 (0.6%) | 4 (4%) | |
| **Valvular infection:** (%) | 2 (1.2%) | 5 (5%) | 0.911 |
| **Bleeding:** (%) | 14 (8.5%) | 12 (12%) | |
| **Severity** (according to BARC definition) | | | |
| - Non serious bleeding (BARC < 3) | 11 (6.7%) | 5 (5%) | Reference |
| - Serious bleeding (BARC ≥ 3) | 3 (1.8%) | 7 (7%) | 0.062 |
| **Site of serious bleeding** | | | |
| - Intracranial hemorrhage | 1 (0.6%) | 4 (4%) | |
| - GI tract bleeding | 2 (1.2%) | 0 | |
| - Joint and muscle bleeding | 0 | 2 (2%) | |
| - Others | 0 | 1 (1%) | |
| **Length of hospital stays**: days | 1 (1; 2) | 9 (9; 16) | <0.001 |

**Table 3. Echocardiographic and cardiac catheterization parameters at baseline and after PTMC**

| Echocardiographic data | Preprocedural | Post procedural | \( P \) Value |
|------------------------|---------------|----------------|--------------|
| MVA by planimetry, cm\(^2\) | 0.94 ± 0.27 | 1.49 ± 0.39 | < 0.001 |
| MVA by PHT, cm\(^2\) | 0.98 ± 0.26 | 1.56 ± 0.38 | < 0.001 |
| Mean PG, mmHg | 12.74 ± 6.11 | 6.12 ± 2.9 | < 0.001 |
| RVSP, mmHg | 54.78 ± 23.10 | 44.42 ± 18.50 | < 0.001 |

**Cardiac catheterization**

| Mean PG, mmHg | 12.63 ± 6.71 | 5.87 ± 3.79 | < 0.001 |
| SPAP, mmHg | 61.74 ± 21.43 | 49.53 ± 17.19 | < 0.001 |
| Mean PAP, mmHg | 40.43 ± 12.94 | 31.66 ± 11.32 | < 0.001 |

Abbreviations: AKI, Acute kidney injury; BARC, Bleeding Academic Research Consortium; MR, Mitral regurgitation; MVR, Mitral valve replacement; PTMC, Percutaneous mitral commissurotomy.

*Median with interquartile range
mechanical valve and 26 patients were implanted with a bioprosthetic valve.

The primary outcome occurred in 22 patients (22%), consisting of all-cause mortality 15%, stroke or systolic embolism 5% and heart failure hospitalization 7%. There was no re-intervention in this group (Figure 1). The periprocedural complications occurred in 16 patients (16%) including re-sternotomy (4%), acute kidney injury required hemodialysis (4%), complete heart block (4%) and death (4%). The valvular infection and serious bleeding (BARC ≥ 3) were 5% and 12%, respectively. The median length of hospital stays was 9 (IQR: 9, 16) days (Table 2).

**Primary and secondary outcomes**

Primary outcome occurred significantly higher in PTMC group (37.2% vs 22%, p = 0.002), as well as, re-intervention (18.3% vs 0%, p < 0.001). However, all-cause mortality (17.1% vs 15%, p = 0.658), stroke or systemic embolism (4.3% vs 5%, p = 0.963), heart failure hospitalization (11.6% vs 7%, p = 0.101), valvular infection (1.2% vs 5%, p = 0.911) and serious bleeding (1.8% vs 7%, p = 0.062) were not significantly different.

**Cox regression and Kaplan-Meier survival analyses**

Potential predictors from univariable analysis were MV intervention with PTMC, older age, DM, HT and SPAP > 50 mmHg as an indication for MV intervention. After adjusted with potential confounding covariates in multivariable analysis; however, PTMC (HR 1.94; 95% confident interval (CI) 1.14, 3.32; p = 0.015), older age (HR 1.03; 95% CI 1.01, 1.06; p = 0.009) and SPAP > 50 mmHg (HR 2.99; 95% CI 1.01, 8.84; p = 0.047) were only predictors of primary outcome (Table 4).

From the Kaplan-Meier curve, MV intervention with PTMC had a significant higher rate of primary outcome (log-rank 4.67; p = 0.031) and re-intervention rate (log-rank 23.12; p < 0.001) than MVR but not for the all-cause mortality (log-rank 0.21; p = 0.649) (Figure 2A-C).

**Discussion**

Unlike most of the previous studies which studied on PTMC or MVR alone, this study evaluated long-term outcomes of patients with clinically significant severe rheumatic MS who underwent MV intervention either PTMC or MVR within 10 years period. We found that the primary composite outcome comprised of all-cause death,

---

**Table 4. Univariate and multivariate cox regression analysis for primary outcome**

|                | Univariate analysis | Multivariate analysis |
|----------------|--------------------|----------------------|
|                | HR     | 95% CI | p-value | HR*    | 95% CI | p-value |
| PTMC           | 1.71   | 1.04, 2.79 | 0.034 | 1.94   | 1.14, 3.32 | 0.015 |
| Age            | 1.04   | 1.02, 1.06 | <0.001 | 1.03   | 1.01, 1.06 | 0.009 |
| Female         | 0.94   | 0.55, 1.60 | 0.815 |        |        |         |
| Atrial fibrillation | 1.42   | 0.86, 2.32 | 0.168 |        |        |         |
| Comorbidity    |        |         |         |        |        |         |
| Type 2 diabetes mellitus | 3.64   | 2.18, 6.09 | <0.001 | 2.29   | 1.00, 5.25 | 0.050 |
| Hypertension   | 2.19   | 1.32, 3.65 | 0.003 | 0.98   | 0.45, 2.16 | 0.960 |
| Dyslipidemia   | 1.51   | 0.76, 3.03 | 0.244 |        |        |         |
| Chronic kidney disease, (GFR < 60 ml/min/1.73 m²) | 2.72   | 0.85, 8.67 | 0.091 | 1.80   | 0.54, 6.03 | 0.343 |
| Indication     |        |         |         |        |        |         |
| Dyspnea        | 0.70   | 0.45, 1.09 | 0.113 | 0.76   | 0.46, 1.26 | 0.287 |
| Heart failure  | 1.37   | 0.88, 2.13 | 0.170 |        |        |         |
| Stroke and systemic embolism | 0.98   | 0.50, 1.90 | 0.949 |        |        |         |
| New-onset atrial fibrillation | 1.04   | 0.58, 1.85 | 0.905 |        |        |         |
| SPAP > 50 mmHg | 3.15   | 1.13, 8.76 | 0.028 | 2.99   | 1.01, 8.84 | 0.047 |
| Planned pregnancy or major surgery | 0.75   | 0.10, 5.44 | 0.778 |        |        |         |
| Preprocedural Echocardiographic data |        |         |         |        |        |         |
| Wilkins’ score | 1.07   | 0.95, 1.21 | 0.270 |        |        |         |
| Wilkins’ score ≥ 8, (%) | 1.16   | 0.66, 2.05 | 0.599 |        |        |         |
| MVA by planimetry, cm² | 0.57   | 0.24, 1.35 | 0.199 |        |        |         |
| Mean PG, mmHg  | 0.96   | 0.92, 1.01 | 0.107 | 1.00   | 0.95, 1.05 | 0.938 |
| RVSP, mmHg     | 1.01   | 0.99, 1.02 | 0.249 |        |        |         |
| Mean PAP, mmHg | 1.01   | 0.98, 1.03 | 0.559 |        |        |         |

Abbreviations: GFR, Glomerular filtration rate; MVA, Mitral valve area; PAP, Pulmonary arterial pressure; PG, pressure gradient; PTMC, Percutaneous mitral commissurotomy; RVSP, Right ventricular systolic pressure; SPAP, Systolic pulmonary arterial pressure.

* Adjusted with factors which p-value in univariate analysis < 0.15
stroke or systemic embolism, heart failure hospitalization and re-intervention was significantly higher in the PTMC group (37.2% vs 22%, p = 0.002). The higher primary outcome in the PTMC group was driven by the incidence of re-intervention (18.3% vs 0%, p < 0.001). However, all-cause death, stroke or systemic embolism and heart failure hospitalization were not significantly different between the two groups. Previous studies reported a wide range of long-term outcomes depending on patient characteristics in each study. All-cause mortality was reported ranging from 0.6 – 14% after PTMC and 6 - 25% after MVR. In this study, all-cause mortality was 17.1% after PTMC and 15% after MVR, supporting the results of the previous studies. In addition, stroke and systemic embolism rate (4 - 5%) was similar to the previous reports (2 – 4%).

Regarding survival analyses, we found that MV intervention with PTMC (HR 1.94; 95% CI 1.14, 3.32; p = 0.015), older age (HR 1.03; 95% CI 1.01, 1.06; p = 0.009) and SPAP > 50 mmHg as an indication for MV intervention (HR 2.99; 95% CI 1.01, 8.84; p = 0.047) increased risk of primary outcome.

After PTMC, the mean MV A was increased by 0.58 cm² which was less than the previous report (0.84 cm²) and the success rate was lower (67.1% vs 80-95%). However, preprocedural MV A in current study was smaller than the previous report by 0.15 cm². Besides, there was a significant proportion (68.3%) of patients with Wilkins' score ≥ 8 in this study, while excluded by previous studies. To our knowledge, MVA before intervention and Wilkins' score were important predictors of PTMC results. Defined by postprocedural MV A > 1.5 cm², many patients were classified as unsuccessful PTMC because MVA was not exceeding 1.5 cm², although, their symptoms and MVA improved. Supported by the re-intervention rate in the current study was similar to other reports (18.3% vs 12 – 40%) and PTMC could delay further intervention by a median of 40.0 (IQR: 10.0, 77.5) months even in patients with Wilkins’ score ≥ 8, hence, unsuccessful PTMC by echocardiographic criteria might not be a good representative of clinical outcomes.

When compared to PTMC, the MVR group had more age and AF, higher Wilkins’ score with smaller MVA indicated more disease severity and chronicity. The median length of hospital stay in the MVR group was 8-day longer than the PTMC group supported the result of the previous study. Periprocedural complications including death were higher in the MVR group, however, long-term outcomes were not different.

Due to a high proportion of patients with Wilkins' score ≥ 8, this study showed evidence that PTMC could be considered and performed successfully in this patient group, especially when MVR was inappropriate or not preferred. Nevertheless, a prospective study should be further investigated to confirm the result.

This study had several limitations. First, this was a retrospective study, therefore outcomes were prone to review bias and subject to confounding from other factors. Second, there was no cardiac catheterization data in the MVR group, hence we could not compare PAP after intervention between groups. Third, this study was conducted in a tertiary referral center where interventionists and surgeons were experienced, thus limiting its generalizability especially in patients with Wilkins’ score ≥ 8 and very small MVA < 1.0 cm².

**Conclusion**

Primary composite outcome occurred in PTMC group more than MVR group which was driven by re-intervention. PTMC group had a higher re-intervention rate, though, it could postpone further invasive procedure by 40 months. Moreover, PTMC could be performed successfully in patients with Wilkins’ score ≥ 8 and might be considered particularly when a patient was not suitable for MVR. All-cause mortality, stroke or systemic embolism, heart failure hospitalization, valvular infection and serious bleeding were not significantly different between two groups.

**Acknowledgements**

We would like to thank all King Chulalongkorn memorial hospital catheterization and noninvasive laboratory staffs involved in this study.

**Funding**

None.
Ethical approval
This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Human Investigation Committee (IRB) of Chulalongkorn University approved this study (IRB no.672/63).

Competing interest
All authors declare that they do not have any conflict of interest.

Supplementary files
Supplementary file contains Table S1.

References
1. Jung B, Vahanian A. Epidemiology of acquired valvular heart disease. Can J Cardiol. 2014;30(9):962-970. doi:10.1016/j.cjc.2014.03.022
2. Kumar RK, Antunes MJ, Beaton A, Mirabel M, Nkomo VT, Okello E, et al. Contemporary diagnosis and management of rheumatic heart disease: implications for closing the gap: a scientific statement from the American Heart Association. Circulation. 2020;142(20):e337-e357. doi:10.1161/cir.0000000000000921
3. Watkins DA, Johnson CO, Colquhoun SM, Karthikeyan G, Beaton A, Buhkman G, et al. Global, regional, and national burden of rheumatic heart disease, 1990-2015. N Engl J Med. 2017;377(8):713-722. doi:10.1056/NEJMoai1603693
4. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PI, et al. ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739-2791. doi:10.1093/eurheartj/ehx391
5. Wunderlich NC, Dalbi V, Ho SY, Kix H, Siegel RJ. Rheumatic mitral valve stenosis: diagnosis and treatment options. Curr Cardiol Rep. 2019;21(3):14. doi:10.1007/s11886-019-1099-7
6. Al Mosa AF, Omair A, Ariﬁ AA, Najm HK. Mitral valve replacement for mitral stenosis: a 15-year single center experience. J Saudi Heart Assoc. 2016;28(4):232-238. doi:10.1016/j.jsja.2016.02.007
7. Borges IP, Peixoto EC, Peixoto RT, Oliveira PS, Netto MS, Labrunie P, et al. Percutaneous mitral balloon valvotomy: Long-term outcome and assessment of risk factors for death and major events. Arq Bras Cardiol. 2005;84(5):397-404. doi:10.1590/s0006-782x2005000500009
8. Bouleti C, Iung B, Lacombe C, Mellet M, Nkomo VT, Okello E, et al. Late results of percutaneous mitral commissurotomy in mitral stenosis: diagnosis and treatment options. Curr Cardiol Rep. 2019;21(3):14. doi:10.1007/s11886-019-1099-7
9. Hamaishi K, Nosaka H, Kimura T, Nakagawa Y, Yokoi H, Iwabuchi M, et al. Ten-years clinical follow-up following successful percutaneous transvenous mitrual commissurotomy: single-center experience. Catheter Cardiovasc Interv. 2000;49(3):284-288. doi:10.1002/(sici)1522-726x(200003)49:3<284::aid-ccid12>:3.0.co;2-h
10. Wilkins GT, Weyman AE, Abascal VM, Block PC, Palacios IF. Percutaneous balloon dilatation of the mitral valve: an analysis of echocardiographic variables related to outcome and the mechanism of dilatation. Br Heart J. 1988;60(4):299-308. doi:10.1136/hrt.60.4.299
11. Inoue K, Owaki T, Nakamura T, Kitamura F, Miyamoto N. Clinical application of transvenous mitral commissurotomy by a new balloon catheter. J Thorac Cardiovasc Surg. 1984;87(3):394-402.
12. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23):2736-2747. doi:10.1161/circulationaha.110.009449
13. Saeki F, Ishizaka Y, Tamura T. Long-term clinical and echocardiographic outcome in patients with mitral stenosis treated with percutaneous transvenous mitral commissurotomy. Jpn Circ J. 1999;63(8):597-604. doi:10.1253/jcj.63.597
14. Kim D, Chung H, Nam JH, Park DH, Shim CY, Kim JS, et al. Predictors of long-term outcomes of percutaneous mitral valvuloplasty in patients with rheumatic mitral stenosis. Yonsei Med J. 2018;59(2):273-278. doi:10.3349/ymj.2018.59.2.273
15. Meneguz-Moreno RA, Costa JR Jr, Gomes NL, Braga SLN, Ramos ALQ, Meneghelo Z, et al. Very long term follow-up after percutaneous balloon mitral valvuloplasty. JACC Cardiovasc Interv. 2018;11(19):1945-1952. doi:10.1016/j.jcin.2018.05.039
16. Russell EA, Tran L, Baker RA, Bennetts JS, Brown A, Reid CM, et al. A review of outcome following valve surgery for rheumatic heart disease in Australia. BMC Cardiovasc Disord. 2015;15:103. doi:10.1186/s12872-015-0094-1
17. Sharma KH, Jain S, Shukla A, Bohora S, Roy B, Gandhi GD, et al. Patient profile and results of percutaneous transvenous mitral valve commissurotomy in mitral restenosis following prior percutaneous transvenous mitral commissurotomy vs surgical commissurotomy. Indian Heart J. 2014;66(2):164-168. doi:10.1016/j.ihj.2013.12.007
18. Inoue K. [Percutaneous transvenous mitral commissurotomy (PTMC) by using Inoue-balloon). Kyobu Geka. 1989;42(8 Suppl):596-602.
19. Nunes MC, Tan TC, Elmariah S, do Lago R, Markey R, Cruz-GonzalezI, et al. The echocardiograms revisited: Impact of incorporating commissural morphology and leaflet displacement to the prediction of outcome for patients undergoing percutaneous mitral valvuloplasty. Circulation. 2014;129(8):886-895. doi:10.1161/circulationaha.113.012522
20. Cohen JM, Glower DD, Harrison JK, Bashore TM, White WD, Smith LR, et al. Comparison of balloon valvuloplasty with operative treatment for mitral stenosis. Ann Thorac Surg. 1993;56(6):1254-1262. doi:10.1016/0003-4975(93)90662-2